Top Markets
#1 Black Phoenix Black Phoenix +166.47%
#2 Islamic Coin Islamic Coin +158.26%
#3 Glidr Glidr +84.34%
#4 Cryptopia Cryptopia +21.05%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.49%
#6 Test Test +17.33%
#7 MarsCoin MarsCoin +12.42%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +11.89%
#9 DOVU DOVU +9.74%
#10 Palladium Network Palladium Network +9.29%
Coin of the day
Black Phoenix Black Phoenix
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc.

VIAP
Rang in Aktien #41780
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily... VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
Aktienkurs
$0.0005
Zuletzt synchronisiert: 2026-08-11
Marktkapitalisierung
$10.28K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel VIA Pharmaceuticals, Inc. (VIAP)

Kategorie

Healthcare
Anzahl der ausstehenden Aktien von VIA Pharmaceuticals, Inc. (VIAP)
Anzahl der ausstehenden Aktien zum August 2026: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von VIA Pharmaceuticals, Inc. beträgt die aktuelle Anzahl der ausstehenden Aktien 0. Am Ende von August 2026 hatte das Unternehmen 0 ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von VIA Pharmaceuticals, Inc. (VIAP) von 2026 bis 2026
Ausstehende Aktien am Ende jedes Jahres
Jahr Ausstehende Aktien ändert
Nicht genügend Daten für die angegebenen Daten.
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
Unternehmen Ausstehende Aktien Unterschied Land
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 445.06M -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 105.38M -
US